Cell line · CVCL_1472
NCI-H1437
Cancer cell line, Homo sapiens. Lung adenocarcinoma. 40 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H1437. Cell lines, record CVCL_1472. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1472
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H1437
- Accession
- CVCL_1472
- RRID
- RRID:CVCL_1472
- Synonyms
- H1437, H-1437, NCIH1437
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 60Y
- Category
- Cancer cell line
- Diseases
- Lung adenocarcinoma (NCIt C3512)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers40
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors. | Cancer Immunol Immunother | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SOCS1 Inhibits IL-6-Induced CD155 Overexpression in Lung Adenocarcinoma. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung Carcinoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 40
See all 40 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HyCyte NCI-H1437 KO-hFANCA | CVCL_F4J0 | Cell lines | |
| Derived from it | NCI-H1437/Cas9-hyg | CVCL_C9BM | Cell lines | |
| From the same person | NCI-BL1437 | CVCL_2639 | Cell lines |
Cell banks5
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-5872 | ATCC | |
| CLS | 305110 | CLS | |
| Hysigen | TCH-C271 | Hysigen | |
| KCLB | 91437 | KCLB | |
| NCI-DCTD | NCI-H1437 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1472
GET https://conductscience.org/api/cell-lines/v1/CVCL_1472/papers?page=2